Drug intelligence / Profile preview

huCD39 mAb

Development stage: Preclinical
Lead developer: Innate Pharma
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

huCD39 mAb is a novel single-epitope anti-CD39 nanobody designed to block CD39, a key ectonucleotidase that drives adenosine production and acts as a critical immunosuppressive checkpoint in cancer. By inhibiting CD39, this nanobody aims to reverse T-cell suppression, enhance T-cell proliferation and functionality, and consequently inhibit tumor growth. Preclinical studies have demonstrated its significant anti-tumor efficacy in immunocompetent mouse models and against ovarian cancer xenografts.

Other names: anti-CD39 nanobodyanti-CD-39 nanobodyanti-CD 39 nanobody

Targets

ENTPD1 (Ectonucleoside triphosphate diphosphohydrolase 1)

Beyond the preview

Go deeper on huCD39 mAb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on huCD39 mAb.

Explore the full profile